Real-time Estimate Cboe Europe 09:23:17 25/06/2024 BST 5-day change 1st Jan Change
1.965 SEK +2.56% Intraday chart for Immunovia AB +32.25% +10.61%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Immunovia Seeks SEK70 Million from Proposed Rights Offering MT
Transcript : Immunovia AB, Q1 2024 Earnings Call, Apr 29, 2024
Immunovia Streamlines Lab Operations with Move to Research Triangle Park, North Carolina CI
Immunovia Appoints Lisa Ford as Clinical Laboratory Director CI
Immunovia AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Immunovia AB Announces Positive Results from the Model-Development Study for Its Next-Generation Pancreatic Cancer Detection Test CI
Immunovia, Proteomedix Create Assays for Pancreatic Cancer Detection Test MT
Immunovia Successfully Develops Assays to Measure Targeted Proteomedix for Its Next-Generation Pancreatic Cancer Test - Moving Forward Towards Model-Development Study CI
Transcript : Immunovia AB, 2023 Earnings Call, Feb 21, 2024
Immunovia AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Immunovia AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Immunovia AB Elects Melissa Farina and Valerie Bogdan-Powers as New Board Members CI
Transcript : Immunovia AB, Q3 2023 Earnings Call, Nov 09, 2023
Immunovia AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Immunovia Shares Surge on Discovery Study for New Pancreatic Cancer Test MT
Immunovia Successfully Completes Discovery Phase of Next-Generation Test Development CI
Immunovia AB Announces Board Appointments CI
Transcript : Immunovia AB, H1 2023 Earnings Call, Aug 30, 2023
Immunovia AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Transcript : Immunovia AB - Special Call
Sweden's Immunovia Redirects Resources Towards Development of New Pancreatic Cancer Detection Test MT
Immunovia to Significantly Restructure to Focus Resources on its Next-Generation Blood Test for Pancreatic Cancer Detection CI
Immunovia AB Announces Board Changes CI
Transcript : Immunovia AB, Q1 2023 Earnings Call, May 23, 2023
Immunovia AB Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Chart Immunovia AB
More charts
Immunovia AB (publ) is a Sweden-based diagnostic company that is developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s test platform called IMMray. Tests are based on antibody biomarker microarray analysis using machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a disease biomarker signature. Immunovia Dx Laboratories locations in USA and Sweden provides laboratory testing services in two accredited reference laboratories.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. IMMNOV Stock
  4. News Immunovia AB
  5. Immunovia Seeks SEK70 Million from Proposed Rights Offering